United States Glucose Monitoring Market Outlook to 2022

Table Of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 What Is This Report About? 7
2.2 Glucose Monitoring Market Segmentation 7
2.3 Definitions of Markets Covered in the Report 8
3 Glucose Monitoring Market, United States 9
3.1 Glucose Monitoring Market, United States, Revenue ($m), 2008-2015 9
3.2 Glucose Monitoring Market, United States, Revenue ($m), 2015-2022 11
3.2.1 Blood Glucose Meters Market, United States, Revenue ($m), by Segment, 2008-2015 13
3.2.2 Blood Glucose Meters Market, United States, Revenue ($m), by Segment, 2015-2022 15
3.3 Glucose Monitoring Market, United States, Volume (Units), 2008-2015 17
3.4 Glucose Monitoring Market, United States, Volume (Units), 2015-2022 19
3.4.1 Blood Glucose Meters Market, United States, Volume (Units), by Segment, 2008-2015 21
3.4.2 Blood Glucose Meters Market, United States, Volume (Units), by Segment, 2015-2022 23
3.5 Glucose Monitoring Market, United States, Average Price ($), 2008-2022 25
3.6 Glucose Monitoring Market, United States, Distribution Share by Revenue ($m), 2014-2015 26
3.7 Glucose Monitoring Market, United States, Company Share by Revenue ($m), 2015 27
4 Overview of Key Companies in United States, Glucose Monitoring Market 29
4.1 LifeScan Inc 29
4.1.1 Company Overview 29
4.2 Bayer HealthCare AG 29
4.2.1 Company Overview 29
4.3 Abbott Laboratories 29
4.3.1 Company Overview 29
4.4 DexCom Inc 29
4.4.1 Company Overview 29
4.5 F. Hoffmann-La Roche Ltd 30
4.5.1 Company Overview 30
4.6 Medtronic plc 30
4.6.1 Company Overview 30
4.7 Becton Dickinson and Co 30
4.7.1 Company Overview 30
4.8 Trividia Health Inc 31
4.8.1 Company Overview 31
4.9 Arkray Inc 31
4.9.1 Company Overview 31
5 Glucose Monitoring Market Pipeline Products 32
6 Financial Deals Landscape 33
6.1 Acquisition 33
6.1.1 BioTelemetry Acquires Telcare Medical Supply and Associated Assets 33
6.1.2 Abbott Labs to Acquire Alere 34
6.1.3 Teleflex Acquires Nostix 36
6.2 Debt Offerings 37
6.2.1 Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 37
6.2.2 Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 39
6.2.3 Thermo Fisher Scientific Raises USD1.2 Billion in Public Offering of Notes 41
6.2.4 Thermo Fisher Scientific Raises USD670.8 Million in Public Offering of 1.375% Notes Due 2028 43
6.2.5 Thermo Fisher Scientific Raises USD1.12 Billion in Public Offering of 1.375% Notes Due 2028 45
6.3 Partnerships 47
6.3.1 WellDoc Enters into Agreement with LifeScan 47
6.3.2 Diasend Partners with Abbott Labs 48
6.4 Venture Financing 49
6.4.1 Intuity Medical Raises USD40 Million in Series 3 Financing 49
6.4.2 Glooko Raises USD8 Million in Financing Round 51
6.4.3 Optiscan Biomedical Raises USD29.5 Million in Financing Round 52
6.4.4 GlySens Raises USD20 Million in Venture Financing 53
7 Recent Developments 54
7.1 Corporate Communications 54
7.1.1 Sep 20, 2016: Livongo Health Lands Dave Engberg from Evernote as Chief Technology Officer 54
7.1.2 Aug 16, 2016: One Drop Expands Diabetes Health and Behavioral Informatics Team With Addition of Chandra Osborn PhD, MPH as Vice President 54
7.1.3 Aug 02, 2016: PositiveID Adds GenArraytion CEO R. Paul Schaudies, Ph.D. to its Board of Advisors 55
7.1.4 Aug 01, 2016: Zynerba Pharmaceuticals Announces Dosing of First Patients in Phase 2 STAR 1 Clinical Study of ZYN002 CBD Gel in Adult Epilepsy Patients with Refractory Focal Seizures 56
7.1.5 Jul 28, 2016: BD Names R. Andrew Eckert To Board Of Directors 57
7.1.6 Jun 28, 2016: WellDoc, a Digital Health Technology Leader, Expands Leadership Team with Roster of Seasoned Healthcare Executives 57
7.1.7 Jun 22, 2016: Johnson & Johnson Announces Retirement of Louise Mehrotra and Appointment of Joseph Wolk as Vice President of Investor Relations 59
7.1.8 Mar 23, 2016: GlucoTrack Maker Names Two New Board Members 59
7.1.9 Feb 26, 2016: Clinical Update On Thetanix For The Treatment Of Paediatric Crohn Disease : 4D Pharma 60
7.1.10 Jan 28, 2016: LivaNova Receives Regulatory Approval in Japan for KORA 250 61
7.1.11 Jan 19, 2016: Johnson & Johnson Announces Actions To Strengthen Medical Devices Leadership Position In Evolving Healthcare Marketplace 62
7.1.12 Jan 08, 2016: BioGaia’s subsidiary IBT has US IND open and Swedish CTA approved for clinical study 63
7.2 Financial Announcements 64
7.2.1 Nov 21, 2016: PositiveID Reports Revenue of $4.6 Million for First Nine Months of 2016, Up 70% from $2.7 Million for First Nine Months of 2015 64
7.2.2 Nov 04, 2016: Alere Reports Third Quarter 2016 Financial Results 64
7.2.3 Nov 03, 2016: BD Announces Results For 2016 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2017 Guidance 65
7.2.4 Nov 01, 2016: Bio-Rad Reports Third-Quarter Currency-Neutral Revenue Growth of 9.1 Percent 67
7.2.5 Nov 01, 2016: DexCom Reports Third Quarter 2016 Financial Results 68
7.2.6 Oct 27, 2016: Thermo Fisher Scientific Reports Third Quarter 2016 Results 69
7.2.7 Oct 18, 2016: Johnson & Johnson Reports 2016 Third-Quarter Results 70
7.2.8 Sep 27, 2016: PositiveID Announces Highlights for Third Quarter 2016 72
7.2.9 Sep 06, 2016: Alere Reports Second Quarter 2016 Financial Results 73
7.2.10 Aug 17, 2016: Alere Reports First Quarter 2016 Financial Results 74
7.2.11 Aug 15, 2016: PositiveID Reports Q2 2016 Revenue of $1.8 Million, Up from $51 Thousand in Q2 2015 75
7.2.12 Aug 08, 2016: Alere Files Form 10-K, Reports Fourth Quarter and Full Year 2015 Financial Results 75
7.2.13 Aug 04, 2016: BD Announces Results For 2016 Third Fiscal Quarter 77
7.2.14 Aug 03, 2016: Bio-Rad Reports Second-Quarter 2016 Financial Results 79
7.2.15 Aug 02, 2016: DexCom Reports Second Quarter 2016 Financial Results 80
7.2.16 Jul 28, 2016: Thermo Fisher Scientific Reports Second Quarter 2016 Results 80
7.2.17 Jul 19, 2016: Johnson & Johnson Reports 2016 Second-Quarter Results 81
7.2.18 Jul 12, 2016: PositiveID Announces Highlights for First Half of 2016 83
7.2.19 Jun 06, 2016: Sangui BioTech: Third Quarter Report 84
7.2.20 Jun 02, 2016: Fuel3D announces first enterprise client scanning solution 85
7.2.21 May 17, 2016: PositiveID Reports Q1 2016 Revenue of $1.7 Million, Up from $0.1M in Q1 2015 86
7.2.22 May 05, 2016: BD Announces Results For 2016 Second Fiscal Quarter 87
7.2.23 Apr 27, 2016: DexCom Reports First Quarter 2016 Financial Results 89
7.2.24 Apr 19, 2016: Johnson & Johnson Reports 2016 First-Quarter Results 89
7.2.25 Apr 11, 2016: SteadyMed Announces Initiation Of Inter Partes Review Proceedings By U.S. Patent And Trademark Office Against A United Therapeutics Patent 91
7.2.26 Mar 10, 2016: Immunotherapeutic Potential of Manocept Platform Reviewed in the Journal Nuclear Medicine and Biology 93
7.2.27 Feb 23, 2016: DexCom Reports Fourth Quarter and Full Year 2015 Financial Results 94
7.2.28 Feb 03, 2016: BD Announces Results For 2016 First Fiscal Quarter 95
7.2.29 Jan 26, 2016: Johnson & Johnson Reports 2015 Fourth-Quarter Results 97
7.3 Legal And Regulatory 99
7.3.1 Dec 08, 2016: Khang & Khang Announces Securities Class Action Lawsuit against Alere and Reminds Investors with Losses to Contact the Firm 99
7.3.2 Dec 07, 2016: Abbott Seeks To Terminate Alere Acquisition 99
7.3.3 Aug 10, 2016: CDC Exercises Contract Option Valued at $11.6 Million to Further Support Emergent BioSolutions’ Vaccinia Immune Globulin 100
7.3.4 Jun 30, 2016: NuVasive Agrees to Settle Patent Litigation With Medtronic 101
7.3.5 Mar 21, 2016: LifeWatch: Supplemental information on Highmark arbitration case 101
7.3.6 Mar 17, 2016: LifeWatch announces arbitration decision in Highmark case 102
7.3.7 Mar 14, 2016: DECN Subsidiaries Sue Johnson & Johnson and Several Divisions for Patent Infringement 102
7.3.8 Feb 29, 2016: Baron & Budd Investigating Potential Lawsuits Against Johnson & Johnson Regarding Link Between Talcum Powder and Ovarian Cancer 103
7.4 Other Significant Developments 103
7.4.1 Dec 14, 2016: One Drop Announces Inaugural Members Of One Drop | Experts Advisory Board 103
7.4.2 Oct 20, 2016: Actor Derek Theler and Dexcom Take Center Stage to Raise Awareness of Diabetes 105
7.4.3 Aug 17, 2016: Livongo for Diabetes Program Generates Positive Clinical, Financial Outcomes 106
7.4.4 Jun 21, 2016: PositiveID’s Mobile Lab Business Completed 80 Projects in the First Half of 2016 107
7.4.5 May 17, 2016: Protagonist Therapeutics to Present New Data on PTG-200 at Digestive Disease Week 2016 108
7.4.6 May 10, 2016: Thermo Fisher Scientific Reports Progress on Global Corporate Social Responsibility 108
7.4.7 May 03, 2016: Sentnyl Therapeutics, Re-Launches Abstral in the United States 109
7.4.8 Apr 06, 2016: Medtronic Statement on U.S. Department of Treasury's Recent Temporary and Proposed Regulations 109
7.5 Product News 110
7.5.1 Sep 12, 2016: Indiana University Research and Technology issued record 53 U.S. patents in 2015-16 110
7.5.2 Jun 28, 2016: Trividia Health Initiates Voluntary Recall of Certain Lots of TRUEread, TRUEbalance, TRUEtrack & TRUEtest blood glucose test strip 112
7.5.3 Apr 26, 2016: New Vigilant Diabetes Management Companion Launched in U.S. That Alerts Users to Risk of Severe Hypoglycemia in Next 24 Hours 112
7.5.4 Mar 09, 2016: Dexcom continuous glucose monitor receivers 113
7.6 Strategy And Business Planning 114
7.6.1 Nov 22, 2016: Highly Pathogenic Bird Flu Spreading Across Europe and Asia; BiondVax’s Universal Flu Vaccine Candidate Also Covers these Potential Pandemic Strains 114
7.6.2 Nov 14, 2016: Diabetes Management Leader Dexcom Expands Presence in EMEA Markets with new Edinburgh HQ 115
7.6.3 Jun 20, 2016: Dexcom to Expand Manufacturing Operations to Greater Phoenix, Arizona 116
7.6.4 Jan 25, 2016: AstraZeneca partners with peers and academia to establish translational research fund 116
7.6.5 Jan 21, 2016: Singularity University and BD Announce Collaboration Dedicated to Address Global Healthcare Challenges 117
8 Appendix 119
8.1 Research Methodology 120
8.1.1 Coverage 120
8.1.2 Secondary Research 120
8.1.3 Primary Research 121
8.1.4 Company Share Analysis 121
8.1.5 Distribution Share Analysis 121
8.1.6 Benchmarking 122
8.2 GlobalData Consulting 122
8.3 Contact Us 122
8.4 Disclaimer 123

List Of Tables
1.1 List of Tables
Table 1: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 10
Table 2: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 12
Table 3: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 14
Table 4: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 16
Table 5: Glucose Monitoring Market, United States, Volume (Units), Historic, 2008-2015 18
Table 6: Glucose Monitoring Market, United States, Volume (Units), Forecast, 2015-2022 20
Table 7: Blood Glucose Meters Market, United States, Volume (Units), Historic, 2008-2015 22
Table 8: Blood Glucose Meters Market, United States, Volume (Units), Forecast, 2015-2022 24
Table 9: Glucose Monitoring Market, United States, Average Price ($), Historic, 2008-2015 25
Table 10: Glucose Monitoring Market, United States, Average Price ($), Forecast, 2015-2022 25
Table 11: Glucose Monitoring Market, United States, Distribution Share by Revenue ($m), USD Constant, 2014-2015 26
Table 12: Glucose Monitoring Market, United States, Company Share by Revenue ($m), USD Constant, 2015 28
Table 13: Glucose Monitoring Market Pipeline Products 32
Table 14: BioTelemetry Acquires Telcare Medical Supply and Associated Assets 33
Table 15: Abbott Labs to Acquire Alere 34
Table 16: Teleflex Acquires Nostix 36
Table 17: Becton Dickinson Prices Public Offering of 1% Notes Due 2022 for USD500 Million 37
Table 18: Becton Dickinson Prices Public Offering of 1.9% Notes Due 2026 for USD500 Million 39
Table 19: Thermo Fisher Scientific Raises USD1.2 Billion in Public Offering of Notes 41
Table 20: Thermo Fisher Scientific Raises USD670.8 Million in Public Offering of 1.375% Notes Due 2028 43
Table 21: Thermo Fisher Scientific Raises USD1.12 Billion in Public Offering of 1.375% Notes Due 2028 45
Table 22: WellDoc Enters into Agreement with LifeScan 47
Table 23: Diasend Partners with Abbott Labs 48
Table 24: Intuity Medical Raises USD40 Million in Series 3 Financing 49
Table 25: Glooko Raises USD8 Million in Financing Round 51
Table 26: Optiscan Biomedical Raises USD29.5 Million in Financing Round 52
Table 27: GlySens Raises USD20 Million in Venture Financing 53

List Of Figures
1.2 List of Figures
Figure 1: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 9
Figure 2: Glucose Monitoring Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 11
Figure 3: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, Historic, 2008-2015 13
Figure 4: Blood Glucose Meters Market, United States, Revenue ($m), USD Constant, Forecast, 2015-2022 15
Figure 5: Glucose Monitoring Market, United States, Volume (Units), Historic, 2008-2015 17
Figure 6: Glucose Monitoring Market, United States, Volume (Units), Forecast, 2015-2022 19
Figure 7: Blood Glucose Meters Market, United States, Volume (Units), Historic, 2008-2015 21
Figure 8: Blood Glucose Meters Market, United States, Volume (Units), Forecast, 2015-2022 23
Figure 9: Glucose Monitoring Market, United States, Company Share (%) 2015 27

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.